RecruitingNot ApplicableNCT05940272

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers


Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

48 participants

Start Date

Jul 3, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.


Eligibility

Min Age: 18 Years

Inclusion Criteria12

  • Providers
  • Currently a an MSK provider caring for patients with DLBCL (including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and treated as large-cell lymphoma)
  • Patients
  • Per medical record, is currently being treated by a provider who is participating in this study (for the purposes of this study, "treating provider" will be defined as any provider who provides care related to the patient's lymphoma diagnosis)
  • Per medical record, has a diagnosis of DLBCL including DLBCL-transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) which are histologically similar and clinically treated as large-cell lymphoma
  • Per medical record, relapse/ refractory disease within 12 months of 4 cycles of first line therapy OR relapse after 2 cycles of later line therapy or or autologous stem cell transplant (ASCT)
  • Self-identify as Black and/or White
  • Per medical record, 18 years of age or older
  • Per self-report, fluent in English\*\*
  • Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify English fluency necessary for participation in the study:
  • How well do you speak English? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
  • What is your preferred language for healthcare? (must respond English)

Exclusion Criteria6

  • Providers
  • Per self-report, planning to leave the cancer center in the next 12 months
  • Patients
  • Cognitively impaired as demonstrated by (Blessed Orientation- Memory- Concentration (BOMC) score of ≥ 11
  • Per research staff judgment and/or self-report, too ill or weak to complete study procedures
  • Per medical record or self-report, receiving hospice care at the time of enrollment

Interventions

BEHAVIORALHematolo-GIST Training

Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.

BEHAVIORALParticipants Appointment

Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.


Locations(2)

Memorial Sloan Kettering Cancer Center (All protocol activities)

New York, New York, United States

NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only)

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05940272


Related Trials